Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
Trial Parameters
Brief Summary
This phase II trial compares the effect of adding radiation therapy to the usual maintenance therapy with Serplulimab versus Serplulimab alone in patients who have already received Serplulimab plus chemotherapy for the treatment of extensive stage small cell lung cancer .
Eligibility Criteria
Inclusion Criteria: 1. Voluntary participation in clinical studies; fully understand, be informed about the study and have signed the informed consent form (ICF). 2. Male or female aged ≥ 18 and ≤ 75 years, at the time of signing the ICF. 3. Willingness to follow and ability to complete all trial procedures. 4. Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system). 5. No prior systemic therapy for ES-SCLC；at the end of the combination chemotherapy with serplulimab, the efficacy evaluation is CR, PR, or SD. 6. At least one measurable lesion as assessed according to RECIST 1.1 , lesions that have received radiation therapy in the past are only considered measurable if they show clear progression. 7. An ECOG PS score of 0 or 1. 8. An expected survival ≥ 3 months. 9. Normal major organ functions 10. For participants receiving therapeutic anticoagulation: stable anticoagulant regimen 11. Negative human immunodeficie